Clinical Trial Update: Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and tolerability study of alirocumab in patients with hepatic impairment and in healthy subjects has completed. The trial examined how h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED